NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

TSX · Biotechnology · CAD

COSCIENS Biopharma Inc. (CSCI.TO) Stock Analysis

COSCIENS Biopharma Inc. (CSCI.TO) is a Biotechnology stock listed on TSX and quoted in Canadian Dollar.

CSCI.TO

CA$7.40

CA$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CSCI.TO with… →

CSCI.TO Key Statistics

As of Sep 4, 2026
Trading
Open
CA$7.40
Previous Close
CA$7.40
52-Week Range
7.00–39.60
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.90
Valuation
Market Cap
CA$7.85M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.90
EPS (ttm)Profit attributable to each share over the last twelve months.
−7.60
Financials (FY)
Revenue (FY)
CA$7.50M−21.79%
Net Income (FY)
−CA$10.36M
Profit marginThe share of revenue left as profit after all costs and taxes.
75.11%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.06M
1-Year Return
−76.03%
Dividend and dates
Earnings Date
November 10, 2026estimated
Avg Volume
765

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CSCI.TO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−71.05%
2025−26.42%
2024−62.45%
2023−40.23%
2022−62.61%
2021−14.81%
2020−54.62%
2019−70.69%
2018+36.24%
2017−38.43%
2016 (partial year)+4.09%

As of September 4, 2026.

CSCI.TO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025CA$7.50M−CA$10.36M−138.1%
2024CA$9.59M−CA$15.31M−159.7%
2023CA$7.14M−CA$3.49M−48.8%
2022CA$14.57MCA$3.45M23.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025CA$7.50MCA$2.65M−CA$10.37M−CA$10.36M−138.1%
2024CA$9.59MCA$4.73M−CA$14.02M−CA$15.31M−159.7%
2023CA$7.14MCA$2.94M−CA$4.63M−CA$3.49M−48.8%
2022CA$14.57MCA$8.56MCA$4.32MCA$3.45M23.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CSCI.TO Valuation vs Biotechnology Median

Median of 656 stocks
MetricCSCI.TOBiotechnology medianvs median
P/S ratio0.9015.260.1x the median
Profit margin75.11%0.00%75.1 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

COSCIENS Biopharma Inc. (CSCI.TO) is capitalised at CA$7.85M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 28.

The most recent close on file for CSCI.TO is CA$7.40, dated September 4, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from CA$7.00 to CA$39.60. The latest close sits 5.71% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of CA$7.50M. Against the prior fiscal year total of CA$9.59M, that is a change of −21.79%. The same year closed with a net loss of CA$10.36M. Profit margin runs at 75.11%. That is 75.1 percentage points above the Biotechnology median of 0%. Earnings per share on a trailing basis come to −7.6.

Across the 4 fiscal years on file, revenue moves from CA$14.57M in 2022 to CA$7.50M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 0.9. On price-to-sales that is 0.1 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −76.03%. Measured over 10 years, that is −46.88% a year compounded. Beta against the wider market is reported at 1.9. Annualized volatility over the trailing 10 years is 123.51%.

Growth & Income

No dividend is on file for CSCI.TO.

The strongest complete calendar year on file is 2018 at +36.24%; the weakest is 2019 at −70.69%. Of the 9 complete calendar years on file, 1 finished higher. 2026 is still running; the price is −71.05% year to date.

Peer Comparison

COSCIENS Biopharma Inc. (CSCI.TO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
COSCIENS Biopharma Inc. CSCI.TO CA$7.85M —
Vertex Pharmaceuticals Incorporated VRTX CA$138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN CA$85.22B 20.5
argenx SE ARGX CA$64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. COSCIENS Biopharma Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About COSCIENS Biopharma Inc.

COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.

Visit website →